The Career Development Program (CDP) is an essential component of the PNW Prostate SPORE that serves to sustain and enhance our mission by attracting and nurturing new and talented research faculty. The CDP will continue to implement a strategy that has successfully developed clinical, basic, and population scientists for productive careers in translational prostate cancer research.
The specific aims are: 1. Provide research support for junior faculty, advanced fellows, and established investigators who wish to develop or refocus their careers on translational prostate cancer research; 2. Provide a system for mentoring faculty and advanced fellows pursuing prostate cancer research in a broad range of disciplines; 3. Create a framework in which investigators can gain exposure to, and training in, aspects of translational prostate cancer research outside their areas of expertise (e.g., a molecular biologist would be exposed to clinical issues in prostate cancer care by attending tumor boards and clinical prostate cancer conferences); 4. Attract and retain women, minorities and junior faculty who can make key contributions to translational prostate cancer research at the institutions comprising the PNW Prostate SPORE. The CDP will be coordinated between the FHCRC and the University of Washington (UW);the Prostate Centre at the Vancouver General Hospital (VGH);and the Oregon Health Science University (OHSU). Our organizational structure works across sites and includes recruitment and monitoring of candidates by a career development committee, educational coordination through a conference and education committee, and access to more than 45 multidisciplinary investigators both within and outside the SPORE whose research interests provide relevant experience in translational prostate cancer research. The CDP educational program combines a wide spectrum of individual research opportunities, formal educational courses, and a large number of conferences and seminars in translational prostate cancer research. We plan to continue to recruit both qualified faculty members and senior research fellows who wish to expand their work in translational prostate cancer research, focusing on the inclusion of underrepresented minority applicants. In addition to SPORE grant support, this program will be augmented by substantial institutional resources.

Public Health Relevance

Prostate cancer is the second most common cause of cancer deaths in men. Developing translational research scientists in prostate cancer that specialize in clinical, basic, and population sciences research will enhance our understanding of the disease biology, expand treatment options, and improve outcomes for patients.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (M1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Fred Hutchinson Cancer Research Center
United States
Zip Code
Gomez-Sarosi, Luis; Sun, Yu; Coleman, Ilsa et al. (2017) DNA Damage Induces a Secretory Program in the Quiescent TME that Fosters Adverse Cancer Phenotypes. Mol Cancer Res 15:842-851
Urbanucci, Alfonso; Barfeld, Stefan J; Kytölä, Ville et al. (2017) Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer. Cell Rep 19:2045-2059
Jhun, Min A; Geybels, Milan S; Wright, Jonathan L et al. (2017) Gene expression signature of Gleason score is associated with prostate cancer outcomes in a radical prostatectomy cohort. Oncotarget 8:43035-43047
Nguyen, Holly M; Vessella, Robert L; Morrissey, Colm et al. (2017) LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease an--d Serve as Models for Evaluating Cancer Therapeutics. Prostate 77:654-671
Arang, Nadia; Kain, Heather S; Glennon, Elizabeth K et al. (2017) Identifying host regulators and inhibitors of liver stage malaria infection using kinase activity profiles. Nat Commun 8:1232
Lam, Hung-Ming; McMullin, Ryan; Nguyen, Holly M et al. (2017) Characterization of an Abiraterone Ultraresponsive Phenotype in Castration-Resistant Prostate Cancer Patient-Derived Xenografts. Clin Cancer Res 23:2301-2312
Guedes, Liana B; Antonarakis, Emmanuel S; Schweizer, Michael T et al. (2017) MSH2 Loss in Primary Prostate Cancer. Clin Cancer Res 23:6863-6874
Malek, Reem; Gajula, Rajendra P; Williams, Russell D et al. (2017) TWIST1-WDR5-Hottip Regulates Hoxa9 Chromatin to Facilitate Prostate Cancer Metastasis. Cancer Res 77:3181-3193
Green, S M; Kaipainen, A; Bullock, K et al. (2017) Role of OATP transporters in steroid uptake by prostate cancer cells in vivo. Prostate Cancer Prostatic Dis 20:20-27
Lawless, Margaret; Gulati, Roman; Tretiakova, Maria (2017) Stalk versus base invasion in pT1 papillary cancers of the bladder: improved substaging system predicting the risk of progression. Histopathology 71:406-414

Showing the most recent 10 out of 362 publications